MannKind Corporation

We are excited to be part of the 8th Annual IPF Summit in Boston, August 21-22, to speak on “Building a Novel Dry Powder Delivery Platform and Applications in IPF.” MannKind is currently progressing a Phase 1 study with Nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases starting with idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled single- (SAD) and multiple-ascending dose (MAD) study will evaluate the safety, tolerability and pharmacokinetics (PK) of nintedanib inhalation powder in healthy volunteers. #MNKD #IPF #Pulmonary #PulmonaryFibrosis @ipf-summit

As MannKind’s Summer 2024 Internship Program concludes, we want to recognize the positive impact our talented interns have left on our company and thank our incredible mentors for guiding and equipping them for future success.   During their time here, our interns have:   1. Immersed themselves in the biotechnology world, building strong connections with industry professionals. 2. Contributed significantly to their departments through the development and execution of their individual projects. 3. Showcased the skills they learned by presenting their work to MannKind’s Leadership Team, receiving encouragement and feedback.   We had a fantastic time celebrating the interns’ hard work before they head back to school. Their innovative ideas and perspectives have been incredibly refreshing. We cannot wait for next summer, keep an eye out for Summer 2025 internship applications that will be released early next year!   #MannKind #SummerInternship2024

Inhaled insulin continues to be a topic of conversation as MannKind makes it way to New Orleans for #ADCES24, Friday-Monday, August 9-12. We are looking forward to the August 11 presentation (11:25 a.m.) by Kristin Castorino, D.O., BC-ADM, senior investigator at Sansum Diabetes Research Institute, comparing Afrezza vs. usual care in adults with type 1 diabetes from the INHALE-3 study. Come listen in Room 208 or visit with MannKind and its Clinical Education Team in Exhibit Hall B at Booth #937 to learn more about inhaled insulin and our latest developments in the management of diabetes. #MannKind #Diabetes #T1D

August 4 is World NTM Awareness Day! It’s time to shine a light on nontuberculous mycobacterial (NTM) infections and their impact on respiratory health. MannKind is proud to launch LearnAboutNTM.com – an educational website – to coincide with the importance of today. Together, let’s spread awareness about NTM, encourage early detections, improved treatment options, and better support for those affected. Visit worldntmday.org for more ways to get involved. #MannKind #NTMawareness #NTMlungDisease #FightNTM #WorldNTMday @NTMinfo #Pulmonary #WorldNTMawarenessDay

On August 4, MannKind proudly supports World NTM Awareness Day (worldntmday.org). But one day is never enough to continue to spread awareness of nontuberculous mycobacterial (NTM) lung disease as it often goes undiagnosed. We invite you to check out learnaboutntm.com to help understand how to recognize NTM and what it means to have a conversation with a specialist. MannKind received U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension, for the treatment of NTM lung disease, with a Phase 3 study initiated. More details on the study can be found at icon-1study.com. #MannKind #NTMawareness #NTMlungDisease #FightNTM @NTMinfo #WorldNTMday #Pulmonary #WorldNTMawarenessDay

Chances are you have never heard of nontuberculous mycobacteria (NTM) lung disease. That might be because NTM lung disease often goes undiagnosed for years. However, NTM lung disease affects over 100,000 people in the U.S. alone, and the number of cases is increasing worldwide. A diagnosis of chronic lung conditions such as asthma, bronchiectasis or emphysema puts you at higher risk for mycobacterial infection. Mycobacterium avium complex (MAC) is the most common type of NTM bacteria in the U.S. and symptoms and severity vary, especially if you are dealing with another chronic condition. Diagnosing mycobacterial infection can be challenging, but receiving an NTM diagnosis is the first step to treating your MAC symptoms. The most noticeable mycobacterial infection symptom is a chronic cough that produces mucus. As we approach World NTM Awareness Day on August 4, we invite you to learn how to get properly diagnosed by expertly-trained specialists and take the first step to regaining your strength and restoring the quality of your – or a loved one’s – life. Explore learnaboutntm.com. #MannKind #NTMawareness #NTMlungDisease #FightNTM #WorldNTMday #Pulmonary #WorldNTMawarenessDay

On #NationalInternDay MannKind would like to celebrate the 19 outstanding interns across our Danbury and Westlake Village sites. During their 8 weeks working at MannKind, our group of interns will receive real-world experience while working with a knowledgeable mentor in their field. Our interns specialize in professions such as clinical research, manufacturing, legal, engineering, and more. We are amazed to see what they have achieved within the laboratory, corporate offices, and through their community volunteer work. We cannot wait for August when we get to see the interns present their projects that have been brewing. #MannKind #SummerInternship2024

MannKind’s headquarters, nestled near the streets where Danbury Mayor Roberto Alves grew up, welcomed him with open arms today. Mayor Alves joined MannKind CEO Michael Castagna and COO Lauren Sabella and their team to tour the Connecticut facility that manufactures innovative therapeutic products such as inhaled insulin. Sharing what MannKind is doing to help patients living with endocrine and orphan lung diseases are special moments in our books. #MannKind #DanburyCT

Super exciting times ahead!

Looking forward to Scotland and conversations at the 7th World Bronchiectasis Conference, July 4-6. MannKind is proud to be an industry partner of #WBConf24 and present a poster on Clofazimine Inhalation Suspension for the treatment of NTM Pulmonary Disease. See you in Dundee! #MannKind #NTM #NTMlungDisease #LungDisease